Compare · head to head
Innovent Biologics vs Samsung Epis
Innovent Biologics ranks higher overall — 360 rank 68 vs 20.
Samsung Epis leads on Value (53 vs 40). Innovent Biologics leads on Quality (67 vs 50), Safety (62 vs 33) and Sentiment (51 vs 36). The two are close on Growth.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | China | South Korea |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Large | Small |
| ISIN | KYG4818G1010 | KR70126Z0002 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 68 | 20 |
| Value | 40 | 53 |
| Quality | 67 | 50 |
| Growth | 49 | 45 |
| Safety | 62 | 33 |
| Sentiment | 51 | 36 |
| Quality details | ||
| Profitability | 60 | 50 |
| Cash Truth | 74 | 50 |
Innovent Biologics vs CelltrionInnovent Biologics vs MesoblastInnovent Biologics vs GC BiopharmaInnovent Biologics vs Clinuvel PharmaceuticalsAdd a third stock →
Full analyses: Innovent Biologics · Samsung Epis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100